APPLIED MOLECULAR TRANSPORT INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 29th, 2021 • Applied Molecular Transport Inc. • Pharmaceutical preparations • New York
APPLIED MOLECULAR TRANSPORT INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • May 18th, 2020 • Applied Molecular Transport Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [ , 2020] and is between Applied Molecular Transport Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
LEASE AGREEMENTLease Agreement • February 10th, 2021 • Applied Molecular Transport Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 5th day of February, 2021, between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”).
APPLIED MOLECULAR TRANSPORT INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • January 28th, 2022 • Applied Molecular Transport Inc. • Pharmaceutical preparations • New York
Applied Molecular Transport Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC and JMP Securities LLC (collectively the “Agents,” and each individually an “Agent”), as follows:
ContractLetter Agreement • June 1st, 2020 • Applied Molecular Transport Inc. • Pharmaceutical preparations • California
This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering of the Company’s securities (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
VOTING AGREEMENTVoting Agreement • September 21st, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations • Delaware
This Voting Agreement (this “Voting Agreement”) is being delivered on September [•], 2023 by the person or persons named on the signature pages hereto (collectively, the “Holder”), as the holder of Company Shares (as defined below) of Applied Molecular Transport Inc., a Delaware corporation (the “Company”), to Cyclo Therapeutics, Inc., a Nevada corporation (“Parent”).
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann- Pick Disease Type...Applied Molecular Transport Inc. • September 21st, 2023 • Pharmaceutical preparations
GAINESVILLE, FL and SOUTH SAN FRANCISCO, CA – (Businesswire) – September 21, 2023 – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction (the Merger). Following the closing of the Merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”. The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The transaction
SUMMARY OF BASIC LEASE INFORMATIONExtension Option Rider • May 18th, 2020 • Applied Molecular Transport Inc. • Pharmaceutical preparations
This Lease, which includes the preceding Summary and the exhibits attached hereto and incorporated herein by this reference (the Lease, the Summary and the exhibits to be known sometimes collectively hereafter as the “Lease”), dated as of the date set forth in Section 1 of the Summary, is made by and between AP3-SF2 CT SOUTH, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • May 11th, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release (“Agreement”) is made by and between Bittoo Kanwar (“Employee”) and Applied Molecular Transport Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
AGREEMENT FOR MODIFICATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISESAgreement for Modification of Lease • May 11th, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations
This Agreement for Modification of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of May 2, 2023, by and between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”), with reference to the following:
AGREEMENT AND PLAN OF MERGER Among Cyclo Therapeutics, Inc. Cameo Merger Sub, Inc. And Applied Molecular Transport Inc. Dated as of September 21, 2023Agreement and Plan of Merger • September 21st, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER dated as of September 21, 2023 (this “Agreement”), is among Cyclo Therapeutics, Inc., a Nevada corporation (“Parent”), Cameo Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a direct, wholly-owned subsidiary of Parent, and Applied Molecular Transport Inc., a Delaware corporation (the “Company”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • May 11th, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release (“Agreement”) is made by and between Tahir Mahmood (“Employee”) and Applied Molecular Transport Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
THIRD AMENDMENT TO LEASELease • May 11th, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of May 2, 2023, but effective as of 11:59 PM Pacific Time on March 31, 2023, by and between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”).
APPLIED MOLECULAR TRANSPORT INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 30, 2019Investors’ Rights Agreement • February 13th, 2020 • Applied Molecular Transport LLC • Pharmaceutical preparations • California
The parties are signing this Amended and Restated Investors’ Rights Agreement as of the date stated in the introductory clause.
APPLIED MOLECULAR TRANSPORT INC. CONSULTING AGREEMENTConsulting Agreement • May 11th, 2023 • Applied Molecular Transport Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is made and entered into as of April 10, 2023 (the “Effective Date”) by and between Applied Molecular Transport Inc., a Delaware corporation having its principal place of business located at 450 East Jamie Court, South San Francisco, CA 94080 (the “Company”), and Lake Sherwood Partners, LLC, a Delaware limited liability company having a principal place of business at 2105 Ray Drive, Burlingame, CA 94010-5422 (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).
